Uncategorized

Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

Published

4 days ago

on

More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s frontrunners.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version